FAPI PET in Systemic Sclerosis Interstitial Lung Disease

ClinicalTrials.gov ID: NCT07925242

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07925242. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Open-label Efficacy And Safety Study of Fibroblast Activation Protein α (FAP)-Directed Radiotracer 68Ga-FAPI-46 As a Positron Emission Tomography (PET) Functional Response Biomarker For Systemic Sclerosis-Associated Interstitial Lung Disease (SSC-ILD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase II open-label efficacy and safety study to evaluate standard of care treatment response measured by PET imaging radiotracer 68Ga-FAPI-46 in 120 subjects with SSc-ILD.

Study identification

NCT ID: NCT07925242
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of California, Los Angeles; Other
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

FAPI tracer Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2026 (Estimated)
Primary completion: Jun 2030 (Estimated)
Completion: Jun 2030 (Estimated)
Last update posted: Nov 12, 2026

2026 – 2030

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
UCLA Division of Rheumatology	Los Angeles	California	90095	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07925242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 15, 2026